Your browser doesn't support javascript.
An immunoinformatic approach towards development of a potent and effective multi-epitope vaccine against monkeypox virus (MPXV).
Mishra, Sarbani; Rout, Madhusmita; Panda, Sunita; Singh, Susheel Kumar; Sinha, Rohan; Dehury, Budheswar; Pati, Sanghamitra.
  • Mishra S; Bioinformatics Division, ICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India.
  • Rout M; Bioinformatics Division, ICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India.
  • Panda S; Mycology Laboratory, ICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India.
  • Singh SK; Vaccine and Diagnostic Laboratory, ICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India.
  • Sinha R; Department of Computer Science and Engineering, National Institute of Technology Patna, Patna, Bihar, India.
  • Dehury B; Bioinformatics Division, ICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India.
  • Pati S; Bioinformatics Division, ICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India.
J Biomol Struct Dyn ; : 1-14, 2023 Jan 02.
Article in English | MEDLINE | ID: covidwho-2187091
ABSTRACT
Monkeypox is a viral zoonotic disease, often transmitted to humans from animals. While the whole world is haggling with the COVID-19 pandemic, the emergence of the monkeypox virus (MPXV) arose as a new challenge to mankind. Till date, numerous cases related to the MPXV have been reported in several countries across the globe, but, its momentary distribution in the current time has left everyone in fright with increasing mortality and limited clinically approved treatments. Therefore, it is of immense importance to develop a potent and highly effective vaccine capable of inducing desired immunogenic responses against the highly contagious MPXV. Herein, using various immunoinformatic and computational biology tools, we made an attempt to develop a multi-epitope vaccine construct against the MPXV which is antigenic, non-allergen and non-toxic in nature and capable of exhibiting immunogenic behavior. The sequence of vaccine construct was designed using the proposed 4 MHC-I, 3 MHC-II and 4 B-cell epitopes linked with suitable adjuvant and linkers. The modeled structure of the vaccine construct was used to assess its interaction with the Toll-like Receptor 4 (TLR4) using ClusPro and HADDOCK. All-atoms molecular dynamics simulation of the MPXV vaccine construct-TLR4 complex followed by a high level of gene expression of the construct within the bacterial system affirmed its stability along with induction of immunogenic response within the host cell. Altogether, our immunoinformatic approach aid in the development of a stable chimeric vaccine construct against MPXV and needs further experimental validation for its immunological relevance and usefulness as a vaccine candidate.Communicated by Ramaswamy H. Sarma.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study Topics: Vaccines Language: English Journal: J Biomol Struct Dyn Year: 2023 Document Type: Article Affiliation country: 07391102.2022.2163426

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study Topics: Vaccines Language: English Journal: J Biomol Struct Dyn Year: 2023 Document Type: Article Affiliation country: 07391102.2022.2163426